COX-2s pending approval may also carry heart risks
The FDA suggested two COX-2 drugs pending approval, Merck’s Arcoxia and Novartis’ Prexige, carry similar cardiovascular risks to Merck’s Vioxx.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.